Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage

被引:41
作者
Becker, A
Fischer, R
Scherbaum, WA
Schneider, M
机构
[1] Univ Hannover, Dept Rheumatol, D-40225 Dusseldorf, Germany
[2] Univ Hannover, Dept Endocrinol, D-40225 Dusseldorf, Germany
关键词
SLICC-ACR; bone density; bone metabolism;
D O I
10.1177/096120330101001108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the present study was to assess the effects of disease severity and demonstrable organ damage as risk factors for the development of osteoporosis in systemic lupus erythematosus (SLE). Sixty-four SLE patients were included. Mean disease duration was 7.7 +/- 5.7 y. Thirty-two patients had persistent organ damage, defined as SLICC-ACR damage score greater than or equal to 1. Disease activity measured by SLAM-2 ranged from 3 to 27. Bone mineral density (BMD) measurements were performed with dual X-ray absorptiometry. In addition, biochemical markers of bone metabolism were studied. BMD was inversely correlated with disease duration, damage score and cumulative glucocorticoid intake, but no correlation was found for current glucocortioid use or with markers of bone metabolism. In a multivariate analysis, body weight, disease duration and damage index fitted best for the prediction of BMD at both lumbar spine and femoral neck. Seven out of 64 patients had osteoporosis according to WHO criteria. In conclusion, severe osteoporosis is uncommon in lupus patients. Disease activity and severity were no major risk factors for loss of BMD in this study, but persistent non-bone-related organ damage was significantly linked to the presence of osteoporosis measured as decreased BMD. Our data suggest that, in addition to patients receiving glucocorticoids, patients with an SLICC-ACR greater than or equal to 1 or a disease duration greater than or equal to 7 y might benefit from regular monitoring of BMD as secondary prevention of damage.
引用
收藏
页码:809 / 814
页数:6
相关论文
共 30 条
[1]  
ABU SM, 1996, ARTHRITIS RHEUM, V39, P1050
[2]  
[Anonymous], 1996, Arthritis Rheum, V39, P1791
[3]  
BECKER A, 2001, IN PRESS Z RHEUMATOL
[4]   Mortality after all major types of osteoporotic fracture in men and women: an observational study [J].
Center, JR ;
Nguyen, TV ;
Schneider, D ;
Sambrook, PN ;
Eisman, JA .
LANCET, 1999, 353 (9156) :878-882
[5]   BONE-DENSITY AT VARIOUS SITES FOR PREDICTION OF HIP-FRACTURES [J].
CUMMINGS, SR ;
BLACK, DM ;
NEVITT, MC ;
BROWNER, W ;
CAULEY, J ;
ENSRUD, K ;
GENANT, HK ;
PALERMO, L ;
SCOTT, J ;
VOGT, TM .
LANCET, 1993, 341 (8837) :72-75
[6]   Steroid-induced osteoporosis in systemic lupus erythematosus [J].
Cunnane, G ;
Lane, NE .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2000, 26 (02) :311-+
[7]   ASSESSMENT OF THE EFFECT OF ORAL CORTICOSTEROIDS ON BONE-MINERAL DENSITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PRELIMINARY-STUDY WITH DUAL ENERGY X-RAY ABSORPTIOMETRY [J].
DHILLON, VB ;
DAVIES, MC ;
HALL, ML ;
ROUND, JM ;
ELL, PJ ;
JACOBS, HS ;
SNAITH, ML ;
ISENBERG, DA .
ANNALS OF THE RHEUMATIC DISEASES, 1990, 49 (08) :624-626
[8]  
Eastell R, 1997, J RHEUMATOL, V24, P1215
[9]   LOSS OF BONE-MINERAL DENSITY IN PREMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
FORMIGA, F ;
MOGA, I ;
NOLLA, JM ;
PAC, M ;
MITJAVILA, F ;
ROIGESCOFET, D .
ANNALS OF THE RHEUMATIC DISEASES, 1995, 54 (04) :274-276
[10]   Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls [J].
Gilboe, IM ;
Kvien, TK ;
Haugeberg, G ;
Husby, G .
ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 (02) :110-115